Polymeric system for dual growth factor delivery

Takeshita, S. et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662–670 (1994).

Takeshita, S. et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90, 11228–11234 (1994).

Baumgartner, I. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114–1123 (1998).

Hendel, R.C. et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101, 118–121 (2000).

Simons, M. et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 102, E73–86 (2000).

Yancopoulos, G.D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242–248 (2000).

Murray, J., Brown, L. & Lange, R. Controlled release of microquantities of macromolecules. Cancer Drug Deliv. 1, 119–123 (1984).

Edelman, E.R., Mathiowitz, E., Langer, R. & Klagsbrun, M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12, 619–626 (1991).

Gombotz, W.R. & Pettit, D.K. Biodegradable polymers for protein and peptide drug delivery. Bioconjug. Chem. 6, 332–351 (1995).

Kuo, P.Y.P. & Saltzman, W.M. Novel systems for controlled delivery of macromolecules. Crit. Rev. Eukaryot. Gene Expr. 6, 59–73 (1996).

Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998).

Mahoney, M. & Saltzman, W. Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain. Proc. Natl. Acad. Sci. USA 96, 4536–4539 (1999).

Lee, K.Y., Peters, M.C., Anderson, K.W. & Mooney, D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 408, 998–1000 (2000).

Shea, L.D., Smiley, E., Bonadio, J. & Mooney, D.J. DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. 17, 551–554 (1999).

Lu, D. & Saltzman, W. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33–37 (2000).

Darland, D.C. & D'Amore, P.A. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 103, 157–158 (1999).

Risau, W. Mechanisms of angiogenesis. Nature 386, 671–674 (1997).

Folkman, J. & D'Amore, P.A. Blood vessel formation: what is its molecular basis? Cell 87, 1153–1155 (1996).

Yancopoulos, G.D., Klagsbrun, M. & Folkman, J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93, 661–664 (1998).

Benjamin, L.E., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591–1598 (1998).

Sheridan, M.H., Shea, L.D., Peters, M.C. & Mooney, D.J. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J. Controlled Release 64, 91–102 (2000).

Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).

Nor, J.E., Christensen, J., Mooney, D.J. & Polverini, P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154, 375–384 (1999).

Rivard, A. et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154, 355–363 (1999).

Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389–395 (2000).

Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55–60 (1997).

Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6, 460–463 (2000).

Reddi, A. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat. Biotechnol. 16, 247–252 (1998).

Weissman, I. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 287, 1442–1446 (2000).

Mooney, D.J., Baldwin, D.F., Suh, N.P., Vacanti, J.P. & Langer, R. Novel approach to fabricate porous sponges of poly(d,l-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 17, 1417–1422 (1996).

Richardson, T.P. & Mooney, D.J. Gas foam processing for tissue engineering applications. In Methods of tissue engineering. (eds Atala, A. & Lanza, R.) 653–662 (Academic Press, San Diego, CA; 2001).

Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L.H. & Langer, R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharmacol. Res. 8, 713–720 (1991).

Murphy, W.L., Peters, M.C., Kohn, D.H. & Mooney, D.J. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 21, 2521–2527 (2000).